Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Harvard Business School
Cantor Fitzgerald
US Army
McKesson
Daiichi Sankyo
QuintilesIMS
Dow
McKinsey

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,795,312

« Back to Dashboard

Which drugs does patent 7,795,312 protect, and when does it expire?

Patent 7,795,312 protects AMITIZA and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.
Summary for Patent: 7,795,312
Title:Method for treating abdominal discomfort
Abstract:A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Kuno; Sachiko (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/745,689
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,795,312

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No ➤ Sign Up ➤ Sign Up METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Accenture
Daiichi Sankyo
Johnson and Johnson
Cerilliant
Cantor Fitzgerald
Dow
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.